Back to Search
Start Over
Paclitaxel-based chemotherapy for aggressive kaposiform hemangioendothelioma of the temporomastoid region: Case report and review of the literature.
- Source :
-
Head & neck [Head Neck] 2013 Aug; Vol. 35 (8), pp. E258-61. Date of Electronic Publication: 2012 Aug 21. - Publication Year :
- 2013
-
Abstract
- Background: Kaposiform hemangioendothelioma (KHE) is a rare vascular tumor of infancy and childhood. This tumor results in poor prognosis, and therefore, development of a more effective treatment is needed.<br />Methods and Results: We describe an 11-year-old boy presenting with left facial palsy caused by aggressive KHE of the left temporomastoid region. He was treated with paclitaxel-based chemotherapy, because of the difficulty with complete surgical resection for anatomic factor, multiple lung metastases on diagnosis, and no response to conventional treatments. This treatment reduced the volume of primary tumor and lung metastatic lesions, but the efficacy was transitory.<br />Conclusions: Paclitaxel-based chemotherapy for aggressive KHE may be effective, therefore the multimodality therapy including paclitaxel of aggressive KHE, particularly in the head and neck, needs to be investigated in further studies.<br /> (Copyright © 2012 Wiley Periodicals, Inc.)
- Subjects :
- Child
Head and Neck Neoplasms pathology
Humans
Lung Neoplasms secondary
Male
Antineoplastic Agents, Phytogenic therapeutic use
Head and Neck Neoplasms therapy
Hemangioendothelioma secondary
Hemangioendothelioma therapy
Kasabach-Merritt Syndrome secondary
Kasabach-Merritt Syndrome therapy
Lung Neoplasms therapy
Paclitaxel therapeutic use
Sarcoma, Kaposi secondary
Sarcoma, Kaposi therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1097-0347
- Volume :
- 35
- Issue :
- 8
- Database :
- MEDLINE
- Journal :
- Head & neck
- Publication Type :
- Academic Journal
- Accession number :
- 22907922
- Full Text :
- https://doi.org/10.1002/hed.23107